← Back

Seed Innovations Ltd

Seed Innovations Limited, is a venture capital firm specializing in early stage investments. The firm prefers to focus on investments in innovative lifestyle, wellness, health, medical cannabis, technology, life sciences, biotech, food science, blockchain technology, longevity of life, pharmaceuticals, artificial intelligence and digital delivery. It typically invests in North America and Europe but will consider investments elsewhere in the world. It seeks to invest in companies having enterprise value up to £100 million ($127.25 million). The firm can take a minority position to full ownership in its investments. It considers investments in companies with significant intellectual property rights. Seed Innovations Limited was founded in 2012 and is based in St Peter Port, Guernsey.

Price · split & dividend adjusted
News & notes moving SEED.LSE
SEED.LSE

Tower Resources raises £400,000 as farm-out deals near completion

Tower Resources has raised £400,000 to bolster working capital while it waits on government approvals in Namibia and Cameroon, with both farm-out deals potentially completing as early as July. Buccaneer Energy reported an 18% rise in proved reserves in an independent review tied to its bank credit facility, with the borrowing base confirmed at $4.45 million and more growth expected as production ramps up. Light Science Technologies secured up to £1.66 million in orders for its passive fire protection division since April's RLUK Injection acquisition, becoming a vertically integrated business spanning installation and material supply. Eco Buildings Group has started building a second-generation AI-enabled manufacturing line in Albania, the first major use of its recent £2.35 million fundraise, with the new line expected to be operational by the fourth quarter. Fieldwork Robotics, backed by Frontier IP Group, picked up a £300,000 investment from SEED Innovations to roll out its soft fruit harvesting robots, with multi-robot fleets potentially on farms from 2027 if trials succeed. ImmuPharma flagged new research suggesting its lead drug candidate could help treat glioblastoma, an aggressive brain cancer, while its main focus remains autoimmune disease.
Yahoo Finance·64dRead more ▾